Data from EMC - Curated by Toby Galbraith - Last updated 10 August 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.

Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

Visit Hyperammonaemia


Obesity

Learn about the complex factors influencing development of obesity

Visit Obesity


Related Content

More information

Category Value
Agency product number EMEA/H/C/000236
Orphan designation No
Date First Approved 25-08-1999
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Apotex Europe B.V.